Is Artivion, Inc. overvalued or undervalued?

As of 17 February 2022, the valuation grade for Artivion, Inc. has moved from fair to risky, indicating a shift in the company's perceived value. The company is currently considered overvalued given its financial metrics, including a Price to Book Value of 4.35, an EV to EBIT of 62.87, and an EV to EBITDA of 32.14. These ratios suggest that the company is trading at a premium compared to its earnings and book value, which raises concerns about its valuation.
In comparison to its peers, Artivion's P/E ratio is notably negative at -111.78, while MiMedx Group, Inc. is valued fairly with a P/E of 21.59 and an EV to EBITDA of 13.06. Other peers like Atrion Corp. are considered very expensive with an EV to EBITDA of 26.22. The overall analysis indicates that Artivion is overvalued, especially when considering its low ROCE of 4.31% and negative ROE of -4.00%. Despite recent stock performance showing a 32.23% return over the past year, the valuation metrics suggest caution for potential investors.